INmune Bio Ownership

INMB
 Stock
  

USD 6.96  0.19  2.66%   

Some institutional investors establish a significant position in stocks such as INmune Bio in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of INmune Bio, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Please see Risk vs Return Analysis.
  
INmune Bio Total Assets Per Share are projected to slightly grow based on the last few years of reporting. The past year's Total Assets Per Share were at 5.60. The current year Net Current Assets as percentage of Total Assets is expected to grow to 84.47, whereas Cash Flow Per Share is forecasted to decline to (1.64) .
INmune Bio has a total of seventeen million nine hundred fourty-six thousand outstanding shares. INmune Bio secures significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

INmune Stock Ownership Analysis

About 35.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.94. Some equities with similar Price to Book (P/B) outperform the market in the long run. INmune Bio recorded a loss per share of 1.92. The entity had not issued any dividends in recent years. INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patients innate immune system to treat disease. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida. Inmune Bio operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people. To learn more about INmune Bio call the company at 858 964 3720 or check out https://www.inmunebio.com.

INmune Bio SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. INmune Bio prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that INmune Bio investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial INmune Bio specific information freely available to individual and institutional investors to make a timely investment decision.
7th of September 2022
Financial Statements and Exhibits. Other Events
View
1st of June 2022
Submission of Matters to a Vote of Security Holders
View
21st of April 2022
Unclassified Corporate Event
View

INmune Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as INmune Bio is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading INmune Bio backward and forwards among themselves. INmune Bio's institutional investor refers to the entity that pools money to purchase INmune Bio's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Yorkbridge Wealth Partners LlcCommon Shares10.4 K64 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K92 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K87 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K106 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K201 K
Yorkbridge Wealth Partners LlcCommon Shares10.4 K182 K
Westside Investment Management IncCommon Shares30.2 K187
Note, although INmune Bio's institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

INmune Bio Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific INmune Bio insiders, such as employees or executives, is commonly permitted as long as it does not rely on INmune Bio's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases INmune Bio insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Be your own money manager

Our tools can tell you how much better you can do entering a position in INmune Bio without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Bollinger Bands Now

   

Bollinger Bands

Use Bollinger Bands indicator to analyze target price for a given investing horizon
All  Next Launch Module

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as INmune Bio using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please see Risk vs Return Analysis. You can also try ETF Directory module to find actively traded Exchange Traded Funds (ETF) from around the world.

Complementary Tools for analysis

When running INmune Bio price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Go
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Go
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Go
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Go
Is INmune Bio's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of INmune Bio. If investors know INmune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about INmune Bio listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
120.6 M
Quarterly Revenue Growth YOY
6.0
Return On Assets
(0.19) 
Return On Equity
(0.41) 
The market value of INmune Bio is measured differently than its book value, which is the value of INmune that is recorded on the company's balance sheet. Investors also form their own opinion of INmune Bio's value that differs from its market value or its book value, called intrinsic value, which is INmune Bio's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because INmune Bio's market value can be influenced by many factors that don't directly affect INmune Bio's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between INmune Bio's value and its price as these two are different measures arrived at by different means. Investors typically determine INmune Bio value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, INmune Bio's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.